Linda Mellby - Immunovia Publ Laboratory Director
| IMMNOV Stock | SEK 0.45 0.01 2.27% |
Director
Ms. Linda Mellby has served as Vice President Research Development at Immunovia AB since 2018. She has previously been Laboratory Director since 2013. Linda has more than 10 years experience of recombinant antibody microarray technology, the Immunovia platform, she has deep knowledge about platform features, technology development as well as clinical applications within oncoproteomics and autoimmunity. She was one of the key researchers managing the development of the Immunovia antibody microarray platform for disease proteomics, conducting extensive work related to process optimizations, standardizations as well as clinical studies. Linda Mellby received her Ph.D. in Immunotechnology from Dept. of Immunotechnology within CREATE Health Translational Cancer Center, Lund University, in 2010, and a MS in Chemistry Engineering in 2004. since 2018.
| Age | 44 |
| Tenure | 7 years |
| Phone | 46 4 62 75 60 00 |
| Web | https://www.immunovia.com |
Immunovia Publ Management Efficiency
The company has return on total asset (ROA) of (0.2617) % which means that it has lost $0.2617 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3789) %, meaning that it generated substantial loss on money invested by shareholders. Immunovia Publ's management efficiency ratios could be used to measure how well Immunovia Publ manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | DIRECTOR Age | ||
| Karin Leandersson | Cantargia AB | 43 | |
| PerAnders Abrahamsson | Camurus AB | 70 | |
| Patricia Delaite | Cantargia AB | 53 | |
| Mark Never | Camurus AB | 58 | |
| Behshad Sheldon | Camurus AB | 56 | |
| Martin Jonsson | Camurus AB | 58 | |
| Thoas Fioretos | Cantargia AB | 53 | |
| Anders MartinLof | Cantargia AB | 48 | |
| Marianne Alexandersson | Camurus AB | 60 | |
| Kerstin Strinnholm | Camurus AB | 59 | |
| Claus Andersson | Cantargia AB | 51 | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.26 |
Immunovia publ AB Leadership Team
Elected by the shareholders, the Immunovia Publ's board of directors comprises two types of representatives: Immunovia Publ inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immunovia. The board's role is to monitor Immunovia Publ's management team and ensure that shareholders' interests are well served. Immunovia Publ's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immunovia Publ's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Mellby, Laboratory Director | ||
| Jeff Borcherding, Immunovia, US | ||
| Philipp Mathieu, CEO Pres | ||
| Karin Liwendahl, Chief Officer |
Immunovia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immunovia Publ a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (201.30) % | |||
| Current Valuation | 536.89 M | |||
| Shares Outstanding | 22.63 M | |||
| Shares Owned By Insiders | 36.15 % | |||
| Shares Owned By Institutions | 4.60 % | |||
| Price To Earning | (57.93) X | |||
| Price To Book | 2.21 X | |||
| Price To Sales | 683.47 X |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Immunovia Stock
Immunovia Publ financial ratios help investors to determine whether Immunovia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immunovia with respect to the benefits of owning Immunovia Publ security.